Stem cell infusion timing and graft-versus-host disease risk in blood cancer patients
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial looks at whether the time when stem cells are infused affects the chance of developing graft-versus-host disease (aGVHD) after a cord blood transplant. It may help find the best timing to improve outcomes for people with blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (like leukemia or lymphoma) that is in complete remission with no detectable cancer cells
- You are scheduled to receive a single-unit cord blood transplant for the first time
- Your performance status is good (ECOG score 0-2, meaning you can do daily activities with little or no help)
- You do not have serious organ failure or active infection
- You agree to be randomly assigned to receive the stem cells at either an earlier or later time point
- You or your legal representative can sign a consent form to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.